Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VIA Equity Fund III K/S invests in GleSYS AB and Portlane AB
Mandate

VIA Equity Fund III K/S invests in GleSYS AB and Portlane AB

May 08, 2018 IT, Telecommunications and Outsourcing

Vinge has advised VIA Equity Fund III K/S, together with the current owners, founders and CEO Glenn Johansson, in connection with the investment in GleSYS AB and Portlane AB through a new, jointly owned, holding structure.

GleSYS and Portlane offer services within colocation, dedicated servers, network and connections, system management and virtual private servers. The companies’ joint turnover is approximately SEK 100 million with good profitability.

Vinge’s team consisted primarily of Johan Winnerblad, Alex Miler, Andrea Ahlgren, Marith Welin-Berger and Viktor Wahlqvist.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026